Since reported data demonstrate that intracellular level of rpL3 can deeply influence cell response to drug treatments, the knowledge of rpL3 status in p53 null cancers may have a significant value in terms of the efficacy of chemotherapy based on 5-FU and L-OHP. This evidence concerns the gene RPL3 and cancer.